FIELD: chemistry.
SUBSTANCE: disclosed is a method of treating or preventing malignant tumours whose cells express EphA4. The method involves administration of the anti-EphA4 antibody, where the antibody has human IgG1, has VH and VL regions, each containing three corresponding CDR. Described is a pharmaceutical composition based on the antibody for use in the said method.
EFFECT: invention can be used in pancreatic cancer therapy.
11 cl, 2 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ISOLATED ANTI-CD30 ANTIBODY (VERSIONS); HOST CELL, METHOD OF OBTAINING CHIMERIC OR HUMANISED VERSION OF ANTI-CD30 ANTIBODIES (VERSIONS), METHOD OF INHIBITING GROWTH OF CELLS CD30+ AND METHOD OF INHIBITING GROWTH OF TUMOUR CELLS EXPRESSING CD30 | 2006 |
|
RU2492186C2 |
| RECOVERED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY AND METHOD OF INHIBITION OF PSMA-EXPRESSING CELL GROWTH | 2006 |
|
RU2421466C2 |
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| HUMANISED CD19 ANTIBODIES AND USING THEM FOR TREATING TRANSPLANTATION-RELATED ONCOLOGICAL AND AUTOIMMUNE DISEASE | 2007 |
|
RU2495882C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER | 2008 |
|
RU2682285C2 |
| ANTIBODIES SPECIFIC TO CLAUDIN 6 (CLDN6) | 2010 |
|
RU2675997C2 |
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
